✓ Translated by DotMD AI Clinical Council Source: Alzheimer's & dementia : the journal of the Alzheimer's Association • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40390253 ↗

Phase III Randomized Trial: TRAILBLAZER-ALZ 4 (N = 148)

Original Paper Title: “TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 148
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab-treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab-treated participants (P < 0.001). Median time to clearance was 359 versus 568 days for donanemab- versus aducanumab-treated participants (P < 0.001).
  • Study Design & Sample: Phase III Randomized Trial published in Alzheimer's & dementia : the journal of the Alzheimer's Association (N = 148 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Alzheimer's & dementia : the journal of the Alzheimer's Association (2025), this phase iii randomized trial evaluating 148 human participants investigated: The phase 3, open-label TRAILBLAZER-ALZ 4 study compared the effect of donanemab versus aducanumab on amyloid plaque (AP) clearance in participants with early symptomatic Alzheimer's disease. Key clinical takeaway: At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab-treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab-treated participants (P < 0.001). Median time to clearance was 359 versus 568 days for donanemab- versus...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-05-15; N = 148; Rigor 82/100): At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab-treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab-treated participants (P < 0.001). Median time to clearance was 359 versus 568 days for donanemab- versus aducanumab-treated participants (P < 0.001).

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: vascular-dementia-unspecified-severity-with-psychotic-disturbance → Condition: vascular-dementia-unspecified-severity-with-mood-disturbance →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40390253: Phase III Randomized Trial: TRAILBLAZER-ALZ 4 (N = 148)

3 of 3 Free Questions Remaining